292 related articles for article (PubMed ID: 19199897)
1. Intravitreal bevacizumab for diabetic retinopathy.
Arevalo JF; Garcia-Amaris RA
Curr Diabetes Rev; 2009 Feb; 5(1):39-46. PubMed ID: 19199897
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture.
Arevalo JF; Sanchez JG; Lasave AF; Wu L; Maia M; Bonafonte S; Brito M; Alezzandrini AA; Restrepo N; Berrocal MH; Saravia M; Farah ME; Fromow-Guerra J; Morales-Canton V;
Curr Diabetes Rev; 2010 Sep; 6(5):313-22. PubMed ID: 20594160
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy for diabetic macular edema.
Al Rashaed S; Arevalo JF
Middle East Afr J Ophthalmol; 2013; 20(4):315-20. PubMed ID: 24339681
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravitreal bevacizumab on macular thickness: exploring serum and vitreous proangiogenic biomarkers in patients with diabetic macular edema.
Malik TG; Ahmed SS; Gul R; Khalil M; Malik AA; Khan M
Turk J Med Sci; 2018 Aug; 48(4):833-839. PubMed ID: 30119160
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.
Faghihi H; Roohipoor R; Mohammadi SF; Hojat-Jalali K; Mirshahi A; Lashay A; Piri N; Faghihi Sh
Eur J Ophthalmol; 2008; 18(6):941-8. PubMed ID: 18988166
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
10. Current intravitreal pharmacologic therapies for diabetic macular edema.
Colucciello M
Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
[TBL] [Abstract][Full Text] [Related]
11. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
[TBL] [Abstract][Full Text] [Related]
12. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.
Chung EJ; Roh MI; Kwon OW; Koh HJ
Retina; 2008; 28(7):957-63. PubMed ID: 18698297
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
14. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
[TBL] [Abstract][Full Text] [Related]
15. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
Chen E; Hsu J; Park CH
Ophthalmic Surg Lasers Imaging; 2009; 40(1):68-70. PubMed ID: 19205502
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
17. Diabetic macular edema.
Lang GE
Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular edema.
Nagasawa T; Naito T; Matsushita S; Sato H; Katome T; Shiota H
J Med Invest; 2009 Aug; 56(3-4):111-5. PubMed ID: 19763022
[TBL] [Abstract][Full Text] [Related]
19. [Intravitreal bevacizumab followed by focal laser for diffuse diabetic macular edema of recent progression. A clinical case].
Moreno-López M; Regueras A
Arch Soc Esp Oftalmol; 2009 Apr; 84(4):209-12. PubMed ID: 19384761
[TBL] [Abstract][Full Text] [Related]
20. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]